Unprecedented Meroterpenoids Exert Anti-inflammatory Activity by Targeting NF-κB and PI3K Signaling Pathways.

Four classes of unprecedented meroterpenoids (1-10), together with 10 new analogues, were isolated from the symbiotic fungi biotransformation extract. Among them, compounds 1-3 were characterized as the inaugural meroterpenoids containing a 5/3/6/6/6 fused carbon ring system. Compounds 4 and 5 were identified as the first meroterpenoids featuring the rare 6/6/6/6 tetracyclic carbon skeleton. Compound 6 stood out as the first meroterpenoid exhibiting a novel 5/3/6/6/5 pentacyclic framework. Notably, compounds 7-10 were reported as a novel 6/6/6/5 carbon skeleton architecture. Furthermore, 1 and 6 showed stronger inhibitory activities against lipopolysaccharide (LPS)-induced nitric oxide (NO) production in RAW 264.7 cells with IC50 values of 7.46 and 6.02 μM, respectively, than the positive control (indomethacin, IC50 = 31.17 μM). Meanwhile, 1 and 6 significantly downregulated the expression of inflammatory enzyme iNOS and also inhibited the phosphorylation of NF-κB, PI3K, and IκB-α in a concentration-dependent manner.